NURPF Company Profile and Key Details
OTC : NURPF
Neuren Pharmaceuticals
$8.69
0.21+2.48%
Open: 4:00 PMPrice Chart
Stock Price Today
Neuren Pharmaceuticals Limited (NURPF) stock surged +2.48%, trading at $8.69 on OTC, up from the previous close of $8.48. The stock opened at $8.69, fluctuating between $8.48 and $8.69 in the recent session.
Stock Snapshot
8.48
Prev. Close
1.1B
Market Cap
8.48
Day Low
54.31
P/E Ratio
0.16
EPS (TTM)
2.18
Cash Flow per Share
8.69
Open
126.32M
Number of Shares
8.69
Day High
86.35%
Free Float in %
1.61
Book Value
400
Volume
Relevant Articles
SEC Fillings
Current Report (8-k)
| Filing Date | Accepted Date | |
|---|---|---|
Annual Report (10-k)
| Filing Date | Accepted Date | |
|---|---|---|
Stock Price History Chart
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Jun 18, 2026 | 8.69 | 8.69 | 8.69 | 8.69 | 200 |
| Jun 16, 2026 | 8.48 | 8.48 | 8.48 | 8.48 | 446 |
| May 11, 2026 | 9.25 | 9.25 | 8.88 | 8.88 | 750 |
| Apr 30, 2026 | 7.83 | 7.83 | 7.83 | 7.83 | 1 |
| Apr 14, 2026 | 8.82 | 8.82 | 8.82 | 8.82 | 2K |
| Mar 17, 2026 | 8.22 | 8.22 | 8.22 | 8.22 | 100 |
| Feb 23, 2026 | 8.53 | 8.53 | 8.53 | 8.53 | 2.01K |
| Feb 10, 2026 | 9.86 | 9.86 | 9.86 | 9.86 | 100 |
| Jan 29, 2026 | 12.02 | 12.02 | 12.02 | 12.02 | 200 |
| Jan 28, 2026 | 12.02 | 12.02 | 12.02 | 12.02 | 100 |
| Jan 27, 2026 | 12.20 | 12.20 | 12.20 | 12.20 | 100 |
| Jan 15, 2026 | 12.91 | 12.91 | 12.91 | 12.91 | 150 |
| Jan 14, 2026 | 15.15 | 15.15 | 15.15 | 15.15 | 1 |
| Dec 31, 2025 | 12.91 | 12.91 | 12.91 | 12.91 | 1K |
| Dec 03, 2025 | 10.97 | 12.45 | 10.97 | 12.45 | 100 |
| Dec 01, 2025 | 11.01 | 11.01 | 11.01 | 11.01 | 2.9K |
| Nov 10, 2025 | 12.25 | 12.25 | 12.25 | 12.25 | 250 |
| Nov 07, 2025 | 12.91 | 12.91 | 12.91 | 12.91 | 190 |
| Nov 04, 2025 | 11.73 | 11.73 | 11.73 | 11.73 | 4.25K |
| Oct 31, 2025 | 13.90 | 13.90 | 13.90 | 13.90 | 70 |
Contact Details
About Company
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.
Company Information
| Employees | 0 |
| Beta | 1.61 |
| Sales or Revenue | $231.93M |
| 5Y Sales Change% | 11.921% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Stock Peers
ODTC
00
Odonate Therapeutics, Inc.$2,849.50GNMSF00
Genmab A/S$268.61CMXHF00
CSL Limited$192.00NONOF00
Novo Nordisk A/S$144.95CSLLY0.75+0.79%
CSL Limited$95.35UCBJY-0.06-0.08%
UCB SA$73.15PHMMF4.3+16.01%
Pharma Mar, S.A.$31.15BVNKF00
Bavarian Nordic A/S$21.20ELOX0.05+0.36%
Eloxx Pharmaceuticals, Inc.$13.98TLPPF00
Telix Pharmaceuticals Limited$11.00Company Overview
Neuren Pharmaceuticals Limited (OTC:NURPF) closed at $8.69 USD, gaining $0.21 (2.48%) from the previous close of $8.48. The stock is currently mid-range between its 52-week high and low $7.70 and $14.80. With a market capitalization of about $1.10 billion, Neuren Pharmaceuticals Limited is classified as a small-cap and shows higher-than-market volatility (beta ~1.59). Key stats such as the average daily volume over the past year has been around 53.00 shares, trading with heavier-than-usual volume. Headquartered in Camberwell, VIC, Neuren Pharmaceuticals Limited operates in the Healthcare sector and the Biotechnology industry. Led by CEO Jonathan Charles Pilcher, the company employs approximately 8 people and listed since November 04, 2009. Neuren Pharmaceuticals Limited is a biopharmaceutical company specializing in the development of treatments for neurological conditions.
Technical Performance
Average 10-day trading volume of 323.00 shares is below the 3-month average of 679.40, indicating normal recent market interest.
Valuation Metrics
Neuren Pharmaceuticals Limited trades at a P/E ratio of 51.59, slightly above the S&P 500 average, with a price-to-sales ratio of 24.23 and a price-to-book ratio of 4.64 trading at moderately above to book value. The P/FCF stands at 12.49, also above market averages.
Dividend & Fair Value
Neuren Pharmaceuticals Limited last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $2.18. This means the shares are trading above this model’s fair value.
Earnings & Analyst Outlook
Neuren Pharmaceuticals Limited earnings surprise history is a mixed track record. The quarter that ended February 25, 2026, missed forecasts by 776.8%. The prior quarter beat by 2.14%. Over the last six quarters, Apple has recorded several small beats. These include -15.1% in February 28, 2024.
Financial & Profitability Overview
On valuation metrics, Neuren Pharmaceuticals trades at a P/E of 51.59, P/S of 24.23 and P/B of 4.64. The current ratio is 76.60 and quick ratio is 76.60. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is 91.09 days.
Quarterly Financial Highlights
The company ended the quarter with $228.54M in cash and short-term investments, a total debt of $0.00, and net debt of - $17.09M. Total assets were $247.97M, with equity of $205.21M. Financials further reflected stability, with operating cash flow of $184.93M, free cash flow of $184.89M, and capital expenditures of - $40.00K.
Price Forecast & Outlook
Our AI price prediction model suggests that Neuren Pharmaceuticals Limited stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term.
Key Takeaways
Valuation shows Neuren Pharmaceuticals Limited trading at a premium to the broader market with a P/E of 51.59.
Frequently Asked Questions
What is the current Neuren Pharmaceuticals Limited (NURPF) stock price?
Neuren Pharmaceuticals Limited (OTC: NURPF) stock price is $8.69 in the last trading session. During the trading session, NURPF stock reached the peak price of $8.69 while $8.48 was the lowest point it dropped to. The percentage change in NURPF stock occurred in the recent session was 2.48% while the dollar amount for the price change in NURPF stock was $0.21.
NURPF's industry and sector of operation?
The OTC listed NURPF is part of Biotechnology industry that operates in the broader Healthcare sector. Neuren Pharmaceuticals Limited designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Who are the executives of NURPF?
Mr. Jonathan Charles Pilcher A.C.A., ACA, B.Sc., BSc (Hons), F.C.A.
Chief Executive Officer, MD & Executive Director
Mr. Jonathan Charles Pilcher A.C.A., ACA, B.Sc., BSc (Hons)
Chief Executive Officer, MD & Director
Mr. Lawrence Glass
Chief Science Officer
Ms. Lauren Frazer C.A.
Chief Financial Officer & Company Sec.
Dr. Liza A. Squires M.D.
Chief Medical Officer
Mr. Gerry Zhao
Vice President of Corporation Devel.
Mr. Lawrence Glass BA (Biology)
Chief Science Officer
Chief Executive Officer, MD & Executive Director
Mr. Jonathan Charles Pilcher A.C.A., ACA, B.Sc., BSc (Hons)
Chief Executive Officer, MD & Director
Mr. Lawrence Glass
Chief Science Officer
Ms. Lauren Frazer C.A.
Chief Financial Officer & Company Sec.
Dr. Liza A. Squires M.D.
Chief Medical Officer
Mr. Gerry Zhao
Vice President of Corporation Devel.
Mr. Lawrence Glass BA (Biology)
Chief Science Officer
How NURPF did perform over past 52-week?
NURPF's closing price is 126.9% higher than its 52-week low of $7.70 where as its distance from 52-week high of $14.80 is -18.63%.
How many employees does NURPF have?
Number of NURPF employees currently stands at 0.
Link for NURPF official website?
Official Website of NURPF is: https://www.neurenpharma.com
How do I contact NURPF?
NURPF could be contacted at phone 613 909 20480 and can also be accessed through its website. NURPF operates from 697 Burke Road, Camberwell, VIC 3124, Australia.
How many shares of NURPF are traded daily?
NURPF stock volume for the day was 400 shares. The average number of NURPF shares traded daily for last 3 months was 53.
What is the market cap of NURPF currently?
The market value of NURPF currently stands at $1.10B with its latest stock price at $8.69 and 126.32M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep